Harel Insurance and Finance, which helped form cancer therapy developer Ayala Pharmaceuticals in November, is among the investors.
Israel-based oncology therapy developer Ayala Pharmaceuticals has secured $17m in a series A round featuring insurance group Harel Insurance and Finance, Fierce Biotech reported on Tuesday.
Venture capital fund Israel Biotech Fund led the round, which included VC firm aMoon. The three series A investors had partnered to set up Ayala in November 2017.
Ayala is developing cancer drugs based on two gamma secretase inhibitors it licensed from pharmaceutical firm Bristol-Myers Squibb (BMS) in December. BMS received an upfront payment…
